Clinical Trials · NCT06139419
The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Sun Yat-sen University
- Enrollment
- 114
- Start date
- Jul 2023
- Locations
- 1 site, China
- Primary endpoint
- Completion rate of immunotherapy